{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:31:38Z","timestamp":1790386298743,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.leukres.2018.09.001","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T12:01:17Z","timestamp":1536408077000},"page":"58-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Recently approved therapies in acute myeloid leukemia: A complex treatment landscape"],"prefix":"10.1016","volume":"73","author":[{"given":"Chetasi","family":"Talati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.09.001_bib0005","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2018.09.001_bib0010","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.09.001_bib0015","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1093\/annonc\/mdl444","article-title":"Normal and malignant hematopoiesis","volume":"18","author":"Fey","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0020","series-title":"SEER Cancer Stat Facts: Acute Myeloid Leukemia","author":"National Cancer Institute","year":"2018"},{"key":"10.1016\/j.leukres.2018.09.001_bib0025","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V60.2.454.454","article-title":"Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study","volume":"60","author":"Yates","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4137\/CMO.S7244","article-title":"Acute myeloid leukemia: focus on novel therapeutic strategies","volume":"6","author":"Lin","year":"2012","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0035","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. V2 (2018)."},{"key":"10.1016\/j.leukres.2018.09.001_bib0040","unstructured":"Rydapt (midostaurin) [package insert]. (2017)."},{"key":"10.1016\/j.leukres.2018.09.001_bib0045","unstructured":"Mylotarg (gemtuzumab ozogamicin) [package insert]. (2017)."},{"key":"10.1016\/j.leukres.2018.09.001_bib0050","unstructured":"Idhifa (enasidenib) [package insert]. (2017)."},{"key":"10.1016\/j.leukres.2018.09.001_bib0055","unstructured":"Vyxeos (CPX-351) [package insert]. (2017)."},{"key":"10.1016\/j.leukres.2018.09.001_bib0060","unstructured":"Tibsovo (ivosidenib) [package insert]. (2018)."},{"key":"10.1016\/j.leukres.2018.09.001_bib0065","series-title":"SEER Cancer Stat Facts: Leukemia","author":"National Cancer Institute","year":"2018"},{"key":"10.1016\/j.leukres.2018.09.001_bib0070","series-title":"Oxford American Handbook of Oncology","first-page":"702","article-title":"Acute myeloid leukemia (AML)","author":"Laubach","year":"2009"},{"key":"10.1016\/j.leukres.2018.09.001_bib0075","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0080","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0085","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0090","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.5858\/arpa.2016-0504-CP","article-title":"Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology","volume":"141","author":"Arber","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.leukres.2018.09.001_bib0095","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bjh.12135","article-title":"Genetic profiling in acute myeloid leukaemia\u2014where are we and what is its role in patient management","volume":"160","author":"Ofran","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0100","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2009-03-209999","article-title":"Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome","volume":"114","author":"Kayser","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0105","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.09.001_bib0110","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.09.001_bib0115","series-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"109","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.leukres.2018.09.001_bib0120","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2012.43.4738","article-title":"Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia","volume":"30","author":"Mrozek","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0125","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children\u2019s Leukaemia Working Parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0135","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0140","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0145","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0150","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0155","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0160","first-page":"515","article-title":"Bioinformatics analysis to determine prognostic mutations of 72 de novo acute myeloid leukemia cases from the Cancer Genome Atlas (TCGA) with 23 most common mutations and no abnormal cytogenetics","volume":"45","author":"Welsh","year":"2015","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.leukres.2018.09.001_bib0165","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1182\/blood-2011-03-340273","article-title":"FLT3\/ITD AML and the law of unintended consequences","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0170","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood-2016-09-693648","article-title":"How I treat FLT3-mutated AML","volume":"129","author":"Pratz","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0175","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4149\/neo_2010_02_170","article-title":"Secondary acute myeloid leukemia \u2013 a single center experience","volume":"57","author":"Szotkowski","year":"2010","journal-title":"Neoplasma"},{"key":"10.1016\/j.leukres.2018.09.001_bib0180","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.09.001_bib0185","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0190","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2379.2379","article-title":"Leukemia associated TP53 mutations in AML patients ARE strongly associated with complex karyotype and poor outcomes","volume":"124","author":"Ferrari","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0195","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/ajh.23834","article-title":"Acute myeloid leukemia: 2014 update on risk-stratification and management","volume":"89","author":"Estey","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0200","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0205","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2016.01.013","article-title":"Allogeneic hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: the role for FLT3 tyrosine kinase inhibitors post-transplantation","volume":"22","author":"Schiller","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.leukres.2018.09.001_bib0210","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ajh.24140","article-title":"Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade","volume":"90","author":"Badar","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0215","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/17474086.2017.1366852","article-title":"Targeted therapies in acute myeloid leukemia: a focus on FLT-3 inhibitors and ABT199","volume":"10","author":"Naqvi","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0220","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/annonc\/mdw015","article-title":"New drugs in acute myeloid leukemia","volume":"27","author":"Kadia","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0225","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.hoc.2017.03.002","article-title":"The development of FLT3 inhibitors in acute myeloid leukemia","volume":"31","author":"Garcia","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.leukres.2018.09.001_bib0230","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"Sept. (26)","key":"10.1016\/j.leukres.2018.09.001_bib0235","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0240","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2018.09.001_bib0245","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0250","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group","volume":"21","author":"Taksin","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.09.001_bib0255","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0260","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7015","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2)","volume":"35","author":"Fathi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0265","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.09.001_bib0270","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0091270008318006","article-title":"Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus","volume":"48","author":"Wang","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0275","volume":"130","author":"Larson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0280","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.09.001_bib0285","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0290","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.clml.2015.02.017","article-title":"A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients","volume":"15","author":"Cooper","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2018.09.001_bib0295","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/phar.1316","article-title":"Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed\/refractory adult patients with acute myeloid leukemia","volume":"33","author":"Williams","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.leukres.2018.09.001_bib0300","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ajh.23924","article-title":"Phase I\/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"90","author":"Strati","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0305","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.09.001_bib0310","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.09.001_bib0315","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.6.6","volume":"126","author":"Stone","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0320","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0325","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0330","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.906.906","article-title":"Survival following allogeneic hematopoietic cell transplantation in older high-risk acute myeloid leukemia patients initially treated with CPX-351 liposome injection versus standard cytarabine and daunorubucin: subgroup analysis of a large phase III trial","volume":"128","author":"Lancet","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0335","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7000","article-title":"Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML","volume":"34","author":"Lancet","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0340","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2018.09.001_bib0345","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2010-08-300871","article-title":"Gemtuzumab ozogamicin: is there room for salvage?","volume":"116","author":"Clarke","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0350","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0355","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 Trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0360","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study","volume":"115","author":"L\u00f6wenberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.001_bib0365","unstructured":"Mylotarg (gemtuzumab ozogamicin) [package insert]. (2000)."},{"key":"10.1016\/j.leukres.2018.09.001_bib0370","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0375","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR Study","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2018.09.001_bib0380","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0385","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0390","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.09.001_bib0395","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.09.001_bib0400","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/leu.2009.214","article-title":"Influence of NPM1 and FLT3-ITD status on outcome in relapsed\/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin","volume":"24","author":"Chevallier","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.09.001_bib0405","series-title":"(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who are FLT3-ITD Positive","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/j.leukres.2018.09.001_bib0410","series-title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/j.leukres.2018.09.001_bib0415","series-title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/j.leukres.2018.09.001_bib0420","series-title":"Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R\/R FLT3 Mutated AML","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/j.leukres.2018.09.001_bib0425","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/j.leukres.2018.09.001_bib0430","series-title":"Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/j.leukres.2018.09.001_bib0435","series-title":"A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3\/internal Tandem Duplications (ITD) Acute Myeloid Leukemia (AML)","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/j.leukres.2018.09.001_bib0440","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ng.3756","article-title":"Precision oncology for acute myeloid leukemia using a knowledge bank approach","volume":"49","author":"Gerstung","year":"2017","journal-title":"Nat. Genet."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:18Z","timestamp":1758934758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618302078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":88,"alternative-id":["S0145212618302078"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.09.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recently approved therapies in acute myeloid leukemia: A complex treatment landscape","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}